Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Posted by Lindsey Winhoffer on Jan 28th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $10.49, for a total transaction of $20,980.00. Following the sale, the president now owns 2,901,138 shares in the company, valued at approximately $30,432,937.62. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Songjiang Ma also recently made the following trade(s):

On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total value of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total value of $25,000.00.
On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total value of $25,400.00.
On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.

Gyre Therapeutics Trading Up 1.7 %

Shares of Gyre Therapeutics stock opened at $11.38 on Tuesday. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $26.37. The firm’s 50 day moving average is $11.14 and its two-hundred day moving average is $12.58.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its stake in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the period. Geode Capital Management LLC grew its stake in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after acquiring an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in Gyre Therapeutics during the 3rd quarter worth approximately $334,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at approximately $166,000. Finally, Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics during the second quarter worth $123,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.